deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT02247479

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Sponsor: Hoffmann-La Roche

Updated 18 times since 2017 Last updated: Jun 17, 2019 Started: Sep 18, 2014 Primary completion: Jan 29, 2018 Completion: Jan 29, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Listed as NCT02247479, this PHASE3 trial focuses on Geographic Atrophy and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 18 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

Show 13 earlier versions
  1. Jul 2019 — Jan 2021 [monthly]

    Terminated PHASE3

  2. May 2019 — Jul 2019 [monthly]

    Terminated PHASE3

    Status: CompletedTerminated

  3. Nov 2018 — May 2019 [monthly]

    Completed PHASE3

    Status: TerminatedCompleted

  4. Oct 2018 — Nov 2018 [monthly]

    Terminated PHASE3

    Status: CompletedTerminated

  5. Sep 2018 — Oct 2018 [monthly]

    Completed PHASE3

  6. Jul 2018 — Sep 2018 [monthly]

    Completed PHASE3

  7. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE3

  8. May 2018 — Jun 2018 [monthly]

    Completed PHASE3

    Status: TerminatedCompleted

  9. Apr 2018 — May 2018 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

  10. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Aug 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  12. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .